Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22276820 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: epirubicin - cyclophosphamide / docetaxel;   Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab;   Drug: paclitaxel;   Drug: paclitaxel + everolimus (RAD001);   Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab;   Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib

Indicates status has not been verified in more than two years